Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yun-Han, Magleby, Reed, Rao, Rema, Walsh, Thomas J., Singh, Harjot K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010353/
https://www.ncbi.nlm.nih.gov/pubmed/33816098
http://dx.doi.org/10.1016/j.mmcr.2021.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010353/
https://www.ncbi.nlm.nih.gov/pubmed/33816098
http://dx.doi.org/10.1016/j.mmcr.2021.03.004

Ejemplares similares